Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (+)-halofuginone
2. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
3. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone Monohydrobromide
4. (-)-halofuginone
5. (-)-halofuginone Hydrobromide
6. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrochloride (1:1), Rel-
7. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrobromide (1:1)
8. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrobromide, Trans-(+-)-
9. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-, Mono(2-hydroxypropanoate)(salt)
10. 6-chloro-7-bromo-(+)-febrifugine
11. 6-chloro-7-bromofebrifugine
12. 7-bromo-6-chloro-3,3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-quinazolinone-hydrolactate
13. 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
14. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
15. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidyl)-2-oxo-propyl)quinazolin-4-one Hydrobromide
16. 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
17. 7-bromo-6-chlorofebrifugine
18. Cebegine
19. Chloro-bromofebrifugine
20. Chlorobromofebrifugine
21. Halagon
22. Halocur
23. Halofuginon
24. Halofuginone Hbr
25. Halofuginone Hcl
26. Halofuginone Hydrobromide
27. Halofuginone Hydrobromide, (-)-
28. Halofuginone Hydrochloride
29. Halofuginone Lactate
30. Halofuginone Monohydrobromide
31. Halofuginone Monohydrochloride
32. Halofuginone, (+)-
33. Halofuginone, (-)-
34. Halofunginone
35. Ru 19110
36. Ru-19110
37. Ru19110
38. Stenorol
39. Trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
1. (+)-halofuginone
2. Halocur
3. Halofuginone, (+)-
4. 6-chloro-7-bromo-(+)-febrifugine
5. 55837-20-2
6. Halofuginon
7. Halofuginona
8. Halofuginonum
9. H84e4y7hc9
10. L31mm1385e
11. (+/-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
12. Halofuginone [inn:ban]
13. 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
14. Halofuginone ((2r,3s) And (2s,3r) Mixture)
15. Halofunginone
16. 7-bromo-6-chloro-3-{3-[(2r,3s)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3h)-one
17. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-
18. 868851-54-1
19. Rel-7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3h)-one
20. Halofuginone [inn]
21. Halofuginonum [inn-latin]
22. Halofuginona [inn-spanish]
23. Unii-l31mm1385e
24. Halocurtm
25. Ht-100
26. 7-bromo-6-chloro-3-[3-[(2r,3s)-3-hydroxy-2-piperidyl]-2-oxo-propyl]quinazolin-4-one
27. Hfg
28. Nsc713205
29. Halofuginone [mi]
30. Unii-h84e4y7hc9
31. Schembl9541147
32. Chembl1199540
33. Dtxsid301339439
34. Zinc5784191
35. S8144
36. Akos022185424
37. Ccg-268823
38. Db04866
39. (+-)-trans-7-brom-6-chlor-3-(3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-chinazolinon
40. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-quinazolinone
41. Trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
42. 4(3h4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-(+/-)-
43. Halofuginone [ema Epar Veterinary]
44. Rel-7-bromo-6-chloro-3-[3-[(2r,3s)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4(3h)-quinazolinone
45. Q4132745
46. (+/-)-trans-7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3h)-quinazolinone Hydrobromide
47. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Rel-
48. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-
49. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-(+-)-
50. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-(+/-)-
51. 7-bromo-6-chloro-3-{3-[(2r,3s)-3-hydroxypiperidin-2-yl]-2-oxopropyl}-3,4-dihydroquinazolin-4-one
Molecular Weight | 414.7 g/mol |
---|---|
Molecular Formula | C16H17BrClN3O3 |
XLogP3 | 1.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 413.01418 g/mol |
Monoisotopic Mass | 413.01418 g/mol |
Topological Polar Surface Area | 82 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 533 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of scleroderma, cancer, and restenosis.
In newborn calves:
- Prevention of diarrhoea due to diagnosed Cryptosporidium parvum infection, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age.
- Reduction of diarrhoea due to diagnosed Cryptosporidium parvum infection. Administration should start within 24 hours after the onset of diarrhoea. In both cases, the reduction of oocysts excretion has been demonstrated.
* In newborn calves:
Prevention of diarrhoea due to diagnosed Cryptosporidium parvum in farms with history of cryptosporidiosis.
Administration should start in the first 24 to 48 hours of age.
Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Administration should start within 24 hours after the onset of diarrhoea.
In both cases, the reduction of oocyst excretion has been demonstrated.
In new born calves:
- Prevention of diarrhoea due to diagnosed Cryptosporidium parvum, in farms with history of cryptosporidiosis,
Administration should start in the first 24 to 48 hours of age
- Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Administration should start within 24 hours after the onset of diarrhoea.
In both cases, the reduction of oocysts excretion has been demonstrated.
Halofuginone, a fully synthetic small molecule, is a potent and selective regulator of stromal cell activation, cell migration and Collagen type I synthesis, a process that has been identified as a 'master switch' in the body's tissue repair process.
Coccidiostats
Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
QP51AX08
QP51AX08
QP51AX08
Absorption
Readily bioavailable and rapidly absorbed following oral administration.
23.8 to 72.1 hours
Halofuginone is a potent inhibitor of collagen a1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also suppresses extracellular matrix deposition and cell proliferation. The profound antitumoral effect of halofuginone is attributed to its combined inhibition of the tumor stromal support, vascularization, invasiveness, and cell proliferation.
ABOUT THIS PAGE
38
PharmaCompass offers a list of Halofuginone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Halofuginone manufacturer or Halofuginone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Halofuginone manufacturer or Halofuginone supplier.
PharmaCompass also assists you with knowing the Halofuginone API Price utilized in the formulation of products. Halofuginone API Price is not always fixed or binding as the Halofuginone Price is obtained through a variety of data sources. The Halofuginone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Halofuginone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Halofuginone, including repackagers and relabelers. The FDA regulates Halofuginone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Halofuginone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Halofuginone supplier is an individual or a company that provides Halofuginone active pharmaceutical ingredient (API) or Halofuginone finished formulations upon request. The Halofuginone suppliers may include Halofuginone API manufacturers, exporters, distributors and traders.
click here to find a list of Halofuginone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Halofuginone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Halofuginone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Halofuginone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Halofuginone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Halofuginone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Halofuginone suppliers with NDC on PharmaCompass.
Halofuginone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Halofuginone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Halofuginone GMP manufacturer or Halofuginone GMP API supplier for your needs.
A Halofuginone CoA (Certificate of Analysis) is a formal document that attests to Halofuginone's compliance with Halofuginone specifications and serves as a tool for batch-level quality control.
Halofuginone CoA mostly includes findings from lab analyses of a specific batch. For each Halofuginone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Halofuginone may be tested according to a variety of international standards, such as European Pharmacopoeia (Halofuginone EP), Halofuginone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Halofuginone USP).